title: Pharma's developing interest in stem cells.
abstract: Human stem cell biology is driving the promise of novel regenerative therapies into clinical trials. Although the pharmaceutical industry has embraced stem cells as tools in drug discovery, few companies have taken the risk to deliver stem cell-based medicines. Here, we evaluate the various cell-based opportunities and corporate strategies.
authors.affiliation: Pfizer Regenerative Medicine, Cambridge, UK. ruth.mckernan@pfizer.com
authors.forename: Ruth
authors.initials: R
authors.lastname: McKernan
authors.forename: John
authors.initials: J
authors.lastname: McNeish
authors.forename: Devyn
authors.initials: D
authors.lastname: Smith
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000191:economics; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D003695:Delivery of Health Care; D055808:Drug Discovery; D004345:Drug Industry / Q000191:economics; D006801:Humans; D013234:Stem Cells